Recruitment status
- Completed10
- Unknown status4
- Active, not recruiting2
- Recruiting2
- Terminated1
Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
United Kingdom trial landscape
Psilocybin Clinical Trials in the United Kingdom
Review psilocybin studies with registry-listed sites in the United Kingdom, including recruitment status, phases, indications, sponsors, and mapped locations.
Registry status is not a guarantee of local availability, eligibility, safety, or efficacy. Confirm every participation decision in the authoritative ClinicalTrials.gov record.
19matching trials
2currently recruiting
153registry-listed sites
Registry facts checkedAug 10, 2026 01:26 UTC
Live registry synthesis
Status, geography, and study phase
Country inclusion is derived from structured trial-site data. Availability and eligibility must be confirmed in the registry because overall trial status can differ from an individual site’s status.
Leading countries
- United Kingdom19
- United States5
- Ireland4
- Czechia3
- Netherlands3
- Canada2
- Denmark2
- Germany2
Trial phases
- Phase 27
- Phase 15
- Not applicable2
- Early Phase 12
- Phase 31
Server-rendered source index
19 matching registry records
Every factual summary is crawlable without JavaScript. Use the direct registry link for current eligibility, contacts, and site availability.
CompletedNCT05723276
Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND)
King's College London
- Conditions
- Functional Neurological Disorder
- Phase
- Not applicable
- Enrollment
- 20 actual
- Locations
- South London and Maudsley NHS Foundation Trust, London, United Kingdom
- Registry updated
- 2026-07-23
CompletedNCT07050368
A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
MycoMedica Life Sciences PBC
- Conditions
- Healthy Volunteer
- Phase
- Phase 1
- Enrollment
- 20 actual
- Locations
- Hammersmith Medicines Research (HMR), London, United Kingdom
- Registry updated
- 2026-02-13
Active, not recruitingNCT05711940
A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 3
- Enrollment
- 572 actual
- Locations
- Lighthouse Psychiatry Scottsdale, Gilbert, Arizona, United States · Clinical Innovations, Inc., Bellflower, California, United States · M3 Wake Research, Encino, California, United States · +113 more
- Registry updated
- 2026-01-12
RecruitingNCT06798636
Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study
Imperial College London
- Conditions
- Self Harm
- Phase
- Early Phase 1
- Enrollment
- 30 estimated
- Locations
- Imperial College London, London, United Kingdom
- Registry updated
- 2025-12-05
RecruitingNCT06815653
Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.
University College, London
- Conditions
- Healthy
- Phase
- Phase 1
- Enrollment
- 40 estimated
- Locations
- University College London, London, United Kingdom
- Registry updated
- 2025-11-26
Active, not recruitingNCT07164755
Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.
King's College London
- Conditions
- Depression - Major Depressive Disorder
- Phase
- Phase not reported
- Enrollment
- 46 actual
- Locations
- King's College London Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom
- Registry updated
- 2025-09-10
CompletedNCT05651126
Modulation of Serotonin Pathways Using Psilocybin in Adults With and Without Autism Spectrum Disorder (ASD)
King's College London
- Conditions
- Autism Spectrum Disorder
- Phase
- Not applicable
- Enrollment
- 67 actual
- Locations
- King's College London, London, United Kingdom
- Registry updated
- 2025-07-28
CompletedNCT05312151
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
COMPASS Pathways
- Conditions
- Post Traumatic Stress Disorder
- Phase
- Phase 2
- Enrollment
- 22 actual
- Locations
- Sunstone Therapies, Rockville, Maryland, United States · Icahn School of Medicine at Mount Sinai, New York, New York, United States · Kings College London, Institute of Psychiatry, Psychology and Neurology, London, United Kingdom
- Registry updated
- 2025-06-13
CompletedNCT05481736
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
COMPASS Pathways
- Conditions
- Anorexia Nervosa
- Phase
- Phase 2
- Enrollment
- 32 actual
- Locations
- Altman Clinical and Translational Research Institute, San Diego, California, United States · Sheppard Pratt Health System, Baltimore, Maryland, United States · Dell Medical School, Austin, Texas, United States · +2 more
- Registry updated
- 2024-12-04
CompletedNCT06258031
PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)
Imperial College London
- Conditions
- Obsessive-Compulsive Disorder
- Phase
- Phase 1
- Enrollment
- 19 actual
- Locations
- CIPPRes Clinic, London, United Kingdom
- Registry updated
- 2024-11-06
CompletedNCT03429075
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
Imperial College London
- Conditions
- Depressive Disorder, Major
- Phase
- Phase 2
- Enrollment
- 59 actual
- Locations
- Imperial College Hammersmith campus, London, United Kingdom
- Registry updated
- 2024-10-24
CompletedNCT04505189
Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study
Imperial College London
- Conditions
- Anorexia Nervosa
- Phase
- Phase 1 · Phase 2
- Enrollment
- 21 actual
- Locations
- Imperial College Hammersmith campus, London, United Kingdom
- Registry updated
- 2024-06-17
Unknown statusNCT05548075
Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action
Imperial College London
- Conditions
- Fibromyalgia
- Phase
- Phase not reported
- Enrollment
- 20 estimated
- Locations
- Imperial College London, London, United Kingdom
- Registry updated
- 2024-01-19
Unknown statusNCT05876481
Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans
Combat Stress
- Conditions
- PTSD
- Phase
- Phase 2
- Enrollment
- 8 estimated
- Locations
- Combat Stress, Leatherhead, Surrey, United Kingdom
- Registry updated
- 2023-05-25
CompletedNCT03775200
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 233 actual
- Locations
- Kadima Neuropsychiatry Institute, La Jolla, California, United States · Altman Clinical and Translational Research Institute, University of California, San Diego, California, United States · Stanford Department of Psychiatry, Stanford, California, United States · +22 more
- Registry updated
- 2023-04-24
TerminatedNCT04905121
An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
Beckley Psytech Limited
- Conditions
- Short Lasting Unilateral Neuralgiform Headache Attacks
- Phase
- Phase 1
- Enrollment
- 4 actual
- Locations
- King's College London, London, United Kingdom
- Registry updated
- 2022-10-12
CompletedNCT04519957
Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase not reported
- Enrollment
- 66 actual
- Locations
- Kadima Neuropsychiatry Institute, La Jolla, California, United States · Altman Clinical and Translational Research Institute, University of California, San Diego, California, United States · Mood and Anxiety Disorders Program Emory University School of Medicine, Atlanta, Georgia, United States · +5 more
- Registry updated
- 2022-09-22
Unknown statusNCT04959253
A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study
King's College London
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 60 estimated
- Locations
- Clinical Research Facility, King's College Hospital, London, United Kingdom
- Registry updated
- 2021-07-22
Unknown statusNCT03661125
A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.
King's College London
- Conditions
- Parkinson Disease Psychosis
- Phase
- Early Phase 1
- Enrollment
- 30 estimated
- Locations
- Mitul Mehta, London, Camberwell, United Kingdom
- Registry updated
- 2019-08-13
Related research views
Continue exploring clinical trials
Move between curated condition, country, phase, and recruiting views without losing direct source provenance.
Recruitment
Conditions
Countries
- United States trials
- Canada trials
- United Kingdom trials
- Switzerland trials
Phases
Method and accountability
How this collection is maintained
Automatic refresh: counts, facets, records, and the map update from the tracker after scheduled ClinicalTrials.gov refreshes. The registry remains authoritative.
Rights-safe scope: the page exposes allowlisted factual metadata. Registry descriptions, contacts, raw payloads, and source-derived keywords are not redistributed.
Editorial review: collection definitions, limitations, corrections, and authorship are documented in the editorial and methodology policy.